17 New Inspection Reports, Including Novartis, Genzyme and Baxter

Share

FDA added 17 Form 483 inspection reports to its public reading room on 11/16-17, including records involving major pharmaceutical and biologics manufacturers in the U.S. and overseas.

The newly disclosed reports include inspections of Novartis Pharma Stein AG in Switzerland, Glenmark Pharmaceuticals in India, Samchundang Pharma in South Korea, Genzyme in Massachusetts and Baxter Healthcare in Illinois.

The newly posted documents also include older inspection reports involving Antaria Pty Ltd. in Australia and Nortec Quimica in Brazil, both dating to 2023.

The following Form 483s were added:

Reports Published November 17, 2026

Establishment

Inspection Date

FDA Report

Novartis Pharma Stein AG — Switzerland

5/19/2026

Form 483

MassBiologics South Coast — Massachusetts

8/12/2024

Form 483

Clement J. Zablocki VA Medical Center — Wisconsin

5/1/2026

Form 483

Reports Published November 16, 2026

Establishment

Inspection Date

FDA Report

Glenmark Pharmaceuticals Limited — India

6/30/2026

Form 483

Samchundang Pharma Co., Ltd. — South Korea

5/19/2026

Form 483

Genzyme Corporation — Massachusetts

4/9/2026

Form 483

Baxter Healthcare Corporation — Illinois

4/2/2026

Form 483

Benjamin D. Elder, MD, PhD — Minnesota

3/27/2026

Form 483

Spectrum Laboratory Products Inc. — California

3/20/2026

Form 483

PETNET Solutions Inc. — Georgia

3/2/2026

PDF link not yet verified

Biomat USA Inc. — Ohio

1/28/2026

Form 483

The Hay Exchange Inc. — Florida

12/5/2025

Form 483

Baxalta US Inc. — California

9/18/2025

Form 483

Read more